MIRA Stock Overview
Operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
MIRA Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.28 |
| 52 Week High | US$5.01 |
| 52 Week Low | US$0.51 |
| Beta | 0 |
| 11 Month Change | -0.78% |
| 3 Month Change | -25.58% |
| 1 Year Change | -64.74% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -82.75% |
Recent News & Updates
Here's Why We're Not Too Worried About MIRA Pharmaceuticals' (NASDAQ:MIRA) Cash Burn Situation
Nov 19
Shareholder Returns
| MIRA | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -8.6% | 2.8% | 2.2% |
| 1Y | -64.7% | 11.8% | 32.6% |
Return vs Industry: MIRA underperformed the US Pharmaceuticals industry which returned 11.8% over the past year.
Return vs Market: MIRA underperformed the US Market which returned 32.6% over the past year.
Price Volatility
| MIRA volatility | |
|---|---|
| MIRA Average Weekly Movement | 16.5% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MIRA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MIRA's weekly volatility has decreased from 91% to 16% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 5 | Erez Aminov | mirapharmaceuticals.com |
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
MIRA Pharmaceuticals, Inc. Fundamentals Summary
| MIRA fundamental statistics | |
|---|---|
| Market cap | US$21.69m |
| Earnings (TTM) | -US$11.24m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.9x
P/E RatioIs MIRA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MIRA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$11.24m |
| Earnings | -US$11.24m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.68 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MIRA perform over the long term?
See historical performance and comparison